Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities.

Annals of hematology - 1 Dec 2003

Thornton Patrick D, Matutes Estella, Bosanquet Andrew G, Lakhani Anil K, Grech Henri, Ropner Janet E, Joshi Rajeev, Mackie Peter H, Douglas Ian D C, Bowcock Stella J, Catovsky Daniel

Abstract excerpt

Abnormalities of the p53 gene are known to confer detrimental effects in chronic lymphocytic leukaemia (CLL) and are associated with short survival. We have used high dose methylprednisolone (HDMP) to treat 25 patients with advanced refractory CLL of whom 45% had p53 abnormalities shown by one or more methods: flow cytometry, fluorescent in situ hybridisation and direct DNA sequencing. Fifteen were resistant to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Screening Assays, Antitumor

Share to Genes, p53

Share to In Situ Hybridization, Fluorescence

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Methylprednisolone

Share to Remission Induction

Source

Identifiers

PMID: 14551737
DOI: 10.1007/s00277-003-0710-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities.PMID 14551737Read ↗

Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy.Semantic proximity Read ↗

Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia.Semantic proximity Read ↗

DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing.Semantic proximity Read ↗

In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.Semantic proximity Read ↗

The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia.Semantic proximity Read ↗

Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAXSemantic proximity Read ↗

p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression.Semantic proximity Read ↗

The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemiaSemantic proximity Read ↗

Studies of glucocorticord resistance in chronic lymphocytic leukaemiaSemantic proximity Read ↗

Chlorambucil in Chronic Lymphocytic Leukemia: Mechanism of ActionSemantic proximity Read ↗

P53, MDM-2, BAX and BCL-2 and Drug Resistance in Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.